Terns Pharmaceuticals Inc...

2.92
-0.20 (-6.41%)
At close: Mar 28, 2025, 3:59 PM
2.93
0.09%
After-hours: Mar 28, 2025, 06:41 PM EDT
-6.41%
Bid 2.85
Market Cap 255.35M
Revenue (ttm) n/a
Net Income (ttm) -97.56M
EPS (ttm) -1.12
PE Ratio (ttm) -2.61
Forward PE -3.4
Analyst Buy
Ask 3.21
Volume 501,743
Avg. Volume (20D) 1,408,508
Open 3.10
Previous Close 3.12
Day's Range 2.90 - 3.11
52-Week Range 2.90 - 11.40
Beta -0.31

About TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase ...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 59
Stock Exchange NASDAQ
Ticker Symbol TERN
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for TERN stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 583.76% from the latest price.

Stock Forecasts
1 week ago
+6.69%
Terns Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription
6 months ago
-4.9%
Terns Pharmaceuticals shares are trading lower after the company announced it priced a $150.1 million public offering of 11,919,048 shares at $10.50 per share.